Skip to content

PAR-25-358 NEI R34 planning grant eligibility Guide

Updated 16 official sources

Quick Answer: PAR-25-358 is an active National Eye Institute (NEI) R34 planning grant for future eye and vision clinical trials or epidemiologic studies.

Full answer and how we checked it

It's clinical trial not allowed, pays up to $150,000 in direct costs per year for up to 2 years, and expires January 8, 2028. The October 16, 2026 date has passed, so the next new-application date is February 16, 2027 (resubmissions: November 16, 2026). NEI funded 4 new R34s in FY2026, the most in any year in NIH RePORTER records back to FY2008.

Who this is for: Vision researchers, clinical investigators in ophthalmology and optometry, epidemiology teams, reading and coordinating centers, and the sponsored-research offices that support them, deciding whether a planning R34 is the right step before an NEI clinical study application.

Data note: Grantsights checked NIH PAR-25-358, the NIH R34 activity-code page, NIH Guide notices on review, Common Forms and funding policy, the Grants.gov listing, USAspending.gov, and the NIH RePORTER API on October 18, 2026.

In this guide

Quick Facts

Agency
HHS
Deadline
Jan 7, 2028
Status
Open

Assistance Listing 93.867: all awards

Source: USASpending.gov FY2024

These figures cover all National Institutes of Health awards under Assistance Listing 93.867, of every award type. They are not figures for the award this guide describes, and one award of that kind can be far smaller.

Total Awards (FY2024, whole listing)
2,876
Avg Award (whole listing)
$2,342,258
Median Award (whole listing)
$1,594,010
Total Funding (FY2024, whole listing)
$689.0M
YoY Funding Trend
-0.4%

Data last verified: May 19, 2026

PAR-25-358 is not a pilot trial grant. According to NIH in PAR-25-358 (opens in a new tab), the route supports planning for eye and vision clinical trials or epidemiologic studies, including a detailed protocol, Manual of Procedures (MOP), statistical analysis plan (SAP), recruitment planning, and feasibility work. NIH also says the grant must not be used to generate intervention-effect data.

That distinction decides most applications. Teams often want an R34 because a future study feels large and uncertain. The right question is narrower: what planning evidence is missing, and can a 2-year award produce the documents and feasibility information NEI needs to fund the later R01, U01, or UG1?

Start with the NEI Clinical Research Study Planning R34 program record. If you're new to NIH mechanisms, the NIH grants complete guide and what is a NOFO cover the basics, and the NHLBI Clinical Trial Pilot R34 guide shows how a different institute writes its R34 rules.

October 2026 Source Check

PAR-25-358 has 2 dates left in 2026 and early 2027 that matter right now. According to NIH in PAR-25-358 (opens in a new tab), the October 16, 2026 new-application date has passed. The next dates are November 16, 2026 for resubmissions and February 16, 2027 for new applications, followed by March 16, 2027 for resubmissions. Applications are due by 5 p.m. local time of the applicant organization, and the NOFO expires January 8, 2028.

A February 16, 2027 application goes to scientific merit review in July 2027, advisory council in October 2027, and an earliest start of December 2027, per the NOFO's key-dates table. A January 28, 2026 notice, NOT-OD-26-029 (opens in a new tab), removed the separate AIDS due dates, so every remaining cycle uses the standard February, June, and October dates.

The NOFO also carries a March 31, 2025 banner saying it was updated to align with agency priorities and asking applicants to reread the full text before submitting. Treat any template built from the 2022 version (PAR-22-128) as stale.

PAR-25-358 cycleNew applicationResubmissionEarliest start
Cycle that just closedOctober 16, 2026November 16, 2026 (still open)July 2027
Next cycleFebruary 16, 2027March 16, 2027December 2027
Following cycleJune 16, 2027July 16, 2027April 2028
Last cycle before expiryOctober 16, 2027November 16, 2027July 2028

The resubmission date is the one to watch if you got a summary statement this year. The guide to resubmitting an NIH grant covers the 1-page Introduction and how to answer critiques.

7 PAR-25-358 Eligibility Stop Checks

PAR-25-358 sets 2 rules that end an application before review: no clinical trial implementation and no preclinical or animal data. NEI treats either as non-responsive, and NIH won't review it. Eligible applicants are broad. The NOFO lists higher education institutions, nonprofits, for-profit organizations including small businesses, state, local and tribal governments, and foreign organizations, and it allows foreign components. Cost sharing isn't required.

Stop checkStrong R34 signalRed flag
Study areaEye or vision clinical trial or epidemiologic studyGeneral health study with weak NEI fit
Planning gapProtocol, MOP, SAP, recruitment, or site process still needs workStudy is already ready to launch
Trial statusNo NIH-defined clinical trial during the R34Participants are assigned to test intervention effects
Data scopeFeasibility or procedure refinement onlyEffectiveness or efficacy data collection
Animal workNonePreclinical or animal data are proposed
DeliverableFull study package for a later R01, U01, or UG1Vague planning discussion
MilestonesQuantified progress markersNo go/no-go decisions

A common mistake is treating planning as a soft word for pilot. It isn't. If the R34 collects outcome data on an intervention's effect, the fit breaks, and NEI will call it non-responsive before review.

5 Source Facts Applicants Should Know

According to NIH in PAR-25-358 (opens in a new tab), the funding number is PAR-25-358, the activity code is R34, the clinical-trial status is not allowed, the maximum project period is 2 years, and NEI permits direct costs up to $150,000 per year plus applicable F&A for consortia.

According to the NIH R34 activity-code page (opens in a new tab), an R34 can support initial development of a clinical trial or research project, including team setup, data management tools, oversight, trial design, procedures, and feasibility data. According to USAspending.gov award data (opens in a new tab) for assistance listing 93.867, Vision Research obligations totaled about $690.7 million in FY2024 and $698.0 million in FY2025. The R34 is a tiny slice of that money.

FactSource-backed read
Funding numberPAR-25-358 (reissue of PAR-22-128)
MechanismR34 planning grant
Clinical trial statusNot allowed
BudgetUp to $150,000 direct costs per year, consortium F&A on top
Project periodUp to 2 years
ReviewScientific Review Group convened by NEI
Prior contactNEI strongly encourages consultation 10 weeks before the due date
ExpirationJanuary 8, 2028

The 10-week consultation point is easy to miss. For the February 16, 2027 date, 10 weeks out is December 8, 2026.

What 21 NEI R34 Awards Show

NEI has funded 21 distinct R34 planning projects since FY2008, and 4 of them started in FY2026. Grantsights analysis of NIH RePORTER data found that a funded NEI R34 is rare, costs about $490,000 for the full project, and is followed by an NEI trial award for the same study about one time in three.

Method: Grantsights pulled every NEI-administered R34 from the NIH RePORTER API (opens in a new tab) on October 18, 2026, grouped fiscal-year rows by core project number, summed total costs per project, then matched each investigator's RePORTER profile ID to later NEI U10, UG1, U01, UG3, UH3 and R01 awards, counting a follow-on only when the later award's title and abstract describe the same planned study.

First fiscal yearNew NEI R34 projects
FY20082
FY2012 to FY20154 (1 a year)
FY20181
FY20203
FY2021 to FY20233 (1 a year)
FY20243
FY20251
FY20264
No new awardsFY2009 to FY2011, FY2016, FY2017, FY2019

Three findings change how to plan:

Cost. The median project carried $487,533 in total costs and $312,108 in direct costs across all 21 projects. The 4 FY2026 awards, all under PAR-25-358, ranged from $479,086 to $542,346, and RePORTER records each one as a single FY2026 row covering a project period that ends in 2028. Direct costs above $300,000 for 2 years usually reflect consortium F&A, which sits outside the $150,000 cap.

Follow-on. Of the 12 R34 projects that started from FY2008 through FY2022, 4 (33%) were followed by an NEI U10 or UG1 award to the same investigator for the same study. For example, UCSF received a 2012 R34 for Jeremy Keenan's Parasitic Ulcer Treatment Trial planning grant, and the trial itself was funded as UG1EY033284 in FY2023, 11 years later. Penny Asbell's 2008 essential fatty acids planning grant at Mount Sinai was followed by the U10 Dry Eye Evaluation and Management (DREAM) Study in FY2013. Johns Hopkins received a 2020 R34 to plan a retinitis pigmentosa treatment trial, and NAC Attack, a phase 3 oral N-acetylcysteine trial, was funded as UG1 awards to the same 2 investigators in FY2022. Jeffrey Walline and David Berntsen's 2022 R34 on delaying myopia onset became a UG1 chair's grant in FY2025. The median gap from R34 to trial award was 4 years.

Where the money goes. In the 2 recent matches, the coordinating-center UG1 carried far more funding than the chair's grant. NAC Attack's coordinating center (UG1EY033293) received $18.09 million from FY2022 through FY2026, against $1.72 million for the chair's grant. The myopia-onset coordinating center at Ohio State (UG1EY037202) received $11.05 million in FY2025 and FY2026, against $893,587 for the chair's grant at the University of Houston. An R34 that doesn't plan the coordinating center in detail is planning the smaller half of the study.

The 8 projects without a matched trial award aren't failures by definition. Some may have been funded by another agency or under another investigator, and at least 1 (80VIP, a vision and hearing study of adults 80 and older) planned an epidemiologic study rather than a trial. The 9 R34s that started in FY2023 or later, including the VICTORY prematurity cohort and the ISEE school screening study, are too recent to judge. The honest read is that an R34 buys a credible study package and early peer review of the rationale, not a reserved slot.

How Reviewers Score an R34 Under the 2025 Framework

The Simplified Framework for NIH Peer Review applies to R34 applications due on or after January 25, 2025. According to NIH notice NOT-OD-24-010 (opens in a new tab), R34 is one of 32 research activity codes moved to 3 factors.

FactorWhat it coversHow it's rated
Factor 1: Importance of the ResearchSignificance and innovationScored 1 to 9
Factor 2: Rigor and FeasibilityApproachScored 1 to 9
Factor 3: Expertise and ResourcesInvestigators and environmentAppropriate, or gaps identified (no score)

PAR-25-358 adds 1 NOFO-specific Factor 2 question: whether the specific aims are "necessary and sufficient to make a final decision about the subsequent trial." That's the sentence to design around. Each aim should end in a decision, such as a confirmed sample size, a locked primary outcome, or a go/no-go call on a site model.

The research strategy instructions also ask for standardized data management and quality control, a plan to finish data analysis within the award period, the capability of each proposed site, and milestones. An R34 that reads like a literature review with a timeline is a red flag under Factor 2, because that factor asks whether the aims actually produce the trial decision. The NIH grant score explainer and the guide to reading your NIH summary statement cover how those factor scores roll into an overall impact score.

NIH-Wide Changes That Hit 2026 and 2027 Applications

3 NIH-wide changes since 2025 affect a February 2027 R34 more than anything in the NOFO itself.

Unified Funding Strategy. According to the NIH funding decisions page (opens in a new tab), institutes stopped using payline cutoffs starting with the January 2026 council round. Institutes now weigh peer review information in its entirety alongside mission fit, career stage, available funds, and the total NIH funding each investigator already holds. NIH also says institute directors will set award budgets on actual need, not only the requested amount. For an R34, a good score is necessary but not sufficient: NEI program priority matters, which is one more reason to talk to program staff early. The NIH paylines explainer covers how the old payline system worked.

Indirect costs. NIH's February 7, 2025 notice NOT-OD-25-068 (opens in a new tab) tried to cap indirect costs at 15% on all grants. Federal courts blocked it, and on January 5, 2026 the First Circuit affirmed the ruling against the cap in Massachusetts v. NIH, No. 25-1343 (opens in a new tab). Budget F&A at your institution's negotiated rate and confirm the current position with your sponsored-programs office before submission. The indirect cost rate guide explains how negotiated rates work.

Common Forms. According to NIH notice NOT-OD-26-079 (opens in a new tab), the leniency period ended May 7, 2026. Since May 8, 2026, eRA blocks any application that doesn't use SciENcv-generated Common Forms for the Biographical Sketch and Current and Pending (Other) Support plus the NIH Biographical Sketch Supplement. Each senior or key person also needs a linked ORCID iD, and applications due on or after May 25, 2026 carry the research security training certification under NOT-OD-26-017 (opens in a new tab). Multi-site R34 teams are the ones that get caught, because every site PI needs a compliant form. The NIH biosketch guide walks through the format.

What NIH Doesn't Tell You

Answer these 4 questions, which the NOFO doesn't package for a busy PI. First, the MOP isn't paperwork. It's the proof that the team can run the later study consistently across sites, readers, imaging workflows, recruitment settings, and data systems.

Second, feasibility isn't efficacy. For a hypothetical example, a retina group in Michigan planning a trial could test image-transfer workflow and screening yield across 3 clinics, but it shouldn't assign patients to compare vision outcomes during the R34.

Third, milestones matter more than page count. Reviewers need to know what document, procedure, recruitment signal, or site-readiness result will be done by month 6, month 12, and month 24, and NIH asks that milestones be quantifiable.

Fourth, the next mechanism isn't settled. The 2023 UG1 series, which funded the myopia-onset trial's chair's grant, expired May 26, 2026, and the replacement, PAR-26-119, exists only as a Grants.gov forecast (opens in a new tab) posted March 3, 2026. Write the R34 so the later study fits a cooperative agreement or an R01, and check the NIH Guide before each cycle.

6 Planning Assets That Make This R34 Stronger

Build 6 planning assets at least 8 weeks before the due date. Asset 1 is a protocol gap table that lists the clinical question, population, inclusion and exclusion rules, intervention or exposure if any, comparator, outcome, and analysis gap.

Asset 2 is a Manual of Procedures outline. Include imaging, visual function testing, specimen handling if any, reading-center workflow, adverse-event process, data entry, queries, quality checks, and site training. The NOFO also lists duties of the study chair, clinical sites, coordinating center, and reading center as MOP content.

Asset 3 is a statistical analysis plan skeleton. According to NIH in the NOFO's scope section, the protocol should address sample size estimates with justification and analytic methods, so the R34 should produce enough information to make the later design credible.

Asset 4 is a recruitment and retention memo. The strongest memos show clinic volume, disease prevalence, inclusion criteria, screening yield, refusal risk, retention touches, and accessibility needs for low-vision participants.

Asset 5 is a data standards plan. NIH encourages FHIR, OMOP, FAIR, and DICOM standards for healthcare and imaging data, and NEI points to NOT-EY-24-006 (opens in a new tab) for ocular imaging formats. Every application also needs a Data Management and Sharing Plan; the data management plan guide covers the 2023 policy.

Asset 6 is a later-route map. The R34 should point to an R01, U01, UG1, or another NEI route, and it should say which components (chair, coordinating center, resource center) the later study needs.

5 Route Choices Before Drafting

Compare 5 routes before committing 2 years to planning.

RouteBetter first read when...Status on October 18, 2026
PAR-25-358 R34Planning documents and feasibility are missingOpen; next new date February 16, 2027
Parent R01, clinical trial required (PA-25-305)A single-team trial is ready nowOpen; NEI participates; expires January 8, 2028
NEI UG1 collaborative clinical researchA multi-center trial needs chair, coordinating and resource centers2023 series expired May 26, 2026; PAR-26-119 forecast only
NEI secondary data R21 (PAR-25-357)Existing datasets can answer the question without new participantsOpen; $275,000 direct over 2 years; expires October 17, 2027
NEI U10Legacy cooperative trial structureNo open NOFO; the last one, PAR-14-096, closed in 2016

According to NIH in PA-25-305 (opens in a new tab), NEI is a participating institute on the parent R01 clinical trial required route, which is the realistic home for a smaller trial when the UG1 series is between versions. The NEI secondary data R21 guide covers PAR-25-357, and the NIH R01 guide covers the parent R01.

The best fit is a study that's important enough to plan seriously but not ready enough to implement.

6 Bad-Fit Signals

6 signals mean you should skip this R34 or redirect. First, the R34 would implement a clinical trial. Second, it collects intervention-effect data. Third, it includes preclinical or animal work.

Fourth, the later study is still only a concept: if the trial question, population, intervention, outcome, coordinating center, and site model can't be stated on 1 page, it's too early. Fifth, the planning work is only meeting time with no concrete deliverables. Sixth, the team lacks the coordinating-center, reading-center, statistical, or site partners needed to produce a credible study package. Given that NAC Attack's coordinating center drew more than 10 times the chair's funding, a missing biostatistics or coordinating partner is the biggest red flag.

10-Week R34 Readiness Plan

NEI asks for contact at least 10 weeks before the due date, so a 10-week plan fits the February 16, 2027 cycle. Weeks 1 and 2 (by December 8, 2026) should confirm source status, the clinical-trial-not-allowed boundary, budget, and the future route, and should get the program-staff memo out.

Weeks 3 and 4 should draft the future study one-pager: question, population, intervention or exposure if any, outcome, sites, coordinating center, and data flow. Weeks 5 and 6 should build the MOP outline and site-readiness table, and every senior or key person should generate SciENcv Common Forms.

Weeks 7 and 8 should build the SAP skeleton and recruitment evidence, and lock aims that each end in a decision. Weeks 9 and 10 should finish the research strategy, Data Management and Sharing Plan, and human subjects study record, leaving the last 5 business days for eRA validation errors.

4 Things To Bring To NEI Program Staff

The NOFO lists 3 NEI scientific contacts (Donald Everett, Jimmy Le, and Azadeh Shoaibi), and a short memo at least 10 weeks before the due date saves a cycle. Lead with the future study: question, population, exposure or intervention, primary outcome, and whether it's headed for an R01 or a UG1.

Then list the planning deliverables the R34 will produce, such as the protocol, Manual of Procedures, statistical analysis plan, and recruitment estimates, with a month for each.

State plainly that the R34 won't collect intervention-effect data. Program staff will flag any activity that looks like a trial, and it's better to hear that before submission.

Finally, check who's been funded. NIH RePORTER (opens in a new tab) lists funded NEI R34 projects with titles, institutions, and award amounts. The FY2026 set includes UC Davis (noninvasive imaging endpoints for uveitis trials), the University of Miami (a home-lighting trial to prevent falls in visually impaired adults), UCLA (DELVE, deep learning for low vision rehabilitation), and Boston Children's Hospital (pediatric inherited retinal disorders).

7 Checks Before You Draft

Grantsights checked these 7 points against PAR-25-358 (opens in a new tab), the NIH R34 activity code page (opens in a new tab), the Grants.gov listing (opens in a new tab), and NIH RePORTER.

PAR-25-358 checkAnswer before draftingSource fact behind it
Trial boundaryDoes any aim assign participants to an intervention to measure its effect? If yes, stop.Clinical trial not allowed; non-responsive applications aren't reviewed
Decision aimsDoes each aim end in a decision about the later trial?Factor 2 asks if aims are necessary and sufficient for that decision
BudgetIs the request at or under $150,000 direct per year, with consortium F&A shown separately?4 FY2026 awards ran $479,086 to $542,346 total
Coordinating centerIs the data coordinating plan as detailed as the clinical plan?Coordinating-center UG1s outspent chair's grants by 10x or more
FormsDo all senior and key personnel have SciENcv Common Forms and linked ORCID iDs?Errors block submission since May 8, 2026
Program contactHas NEI seen a 1-page memo 10 weeks before the due date?December 8, 2026 for the February 16, 2027 date
Later routeIs the next mechanism open, or only forecast?UG1 replacement PAR-26-119 is forecast only

If every answer points to planning, the free Grantsights grant database lists PAR-25-358 alongside other open NEI and NIH routes so you can confirm nothing closer fits first.

Sources

Largest awards active in FY2024

One row per recipient, its largest award | 2,876 Assistance Listing records | Avg: $2.3M

REAL DATA
1

Jaeb Center for Health Research Foundation, Inc.

FL

$73.8M
2

European Molecular Biology Laboratory

$48.0M

Use the visible recipient rows as free source context

This program has no reviewed paid report today.

No reviewed paid report is currently offered for this program. The visible source rows remain free.

Next steps

Where to go next

These next pages help you move from research into a specific grant choice.

Frequently Asked Questions

What does PAR-25-358 fund?

It funds planning work for a future eye or vision clinical trial or epidemiologic study: the protocol, Manual of Procedures, statistical analysis plan, data and safety monitoring plan, site standardization, and small feasibility studies that refine procedures or document recruitment potential.

Are clinical trials allowed?

No. PAR-25-358 is clinical trial not allowed. NIH says the grant can't be used to generate data on the effects of a proposed intervention, and applications that implement a clinical trial or collect preclinical or animal data are non-responsive and won't be reviewed.

What budget applies?

NEI permits up to $150,000 in direct costs per year, plus applicable F&A for consortia, for a maximum project period of 2 years. The 4 NEI R34s that started in FY2026 each carried about $479,000 to $542,000 in total costs for the full project in NIH RePORTER.

What is the next deadline?

The October 16, 2026 new-application date has passed. NIH lists November 16, 2026 for resubmissions and February 16, 2027 for new applications, then March 16, 2027 for resubmissions. Applications are due by 5 p.m. local time, and the NOFO expires January 8, 2028.

Does an NEI R34 lead to a funded trial?

Not automatically. NIH says R34 funding doesn't guarantee funding of the full-scale study. Grantsights analysis of NIH RePORTER found that 4 of the 12 NEI R34 projects that started from FY2008 through FY2022 were followed by an NEI U10 or UG1 award to the same investigator for the same planned study.

Is the NEI UG1 clinical trial route open now?

The 2023 UG1 chair's, coordinating center, and resource center NOFOs (PAR-23-209, PAR-23-204, PAR-23-201) expired May 26, 2026. Grants.gov lists a replacement, PAR-26-119 (UG1 Clinical Trial Optional), as a forecast only, with no NIH Guide notice published as of October 18, 2026.

Who should skip this route?

Skip it if the study is already ready for implementation, if the planning work would assign participants to an intervention to measure its effect, or if the project needs preclinical or animal data.

Last updated October 18, 2026. Corrected October 18, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.